Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer

Published by: BioSeeker Group AB

Published: Feb. 6, 2008 - 450 Pages


Table of Contents


Executive Summary

2 Methodologies

3 List of Tables

3.1 List of Boxes

3.2 List of Figures

4 Introduction to Apoptotic Drugs in Oncology

5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

6 The Cancer Genome Project and Apoptopic Drug Targets

6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

7 Protein Expression Profiles of Apoptopic Drug Targets in Human

7.1 Expression in Normal Tissues and Cancer Tissues

7.2 Expression in Human Cancer Cell Lines and Primary Cells

8 Pathway Analysis of Drug Targets of Apoptopic Drugs

9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

10 Available Biological Structure Data on Apoptopic Drug Targets

11 Drug Target Profiles of Apoptopic Drug Targets in Oncology

11.1.1 Auxiliary transport protein activity

11.1.2 Carboxy-lyase activity

11.1.3 Catalytic activity

11.1.4 Cell adhesion molecule activity

11.1.5 Chaperone activity

11.1.6 Complement activity

11.1.7 Cysteine-type peptidase activity

11.1.8 Cytokine activity

11.1.9 DNA topoisomerase activity

11.1.10 Glutathione transferase activity

11.1.11 Hormone activity

11.1.12 Hydrolase activity

11.1.13 Intracellular ligand-gated ion channel activity

11.1.14 Kinase activity

11.1.15 Kinase regulator activity

11.1.16 Ligase activity

11.1.17 Lipid kinase activity

11.1.18 Metallopeptidase activity

11.1.19 Molecular function unknown

11.1.20 Motor activity

11.1.21 Oxidoreductase activity

11.1.22 Peptide hormone

11.1.23 Peroxidase activity

11.1.24 Protein binding

11.1.25 Protein serine/threonine kinase activity

11.1.26 Protein threonine/tyrosine kinase activity

11.1.27 Protein-tyrosine kinase activity

11.1.28 Receptor activity

11.1.29 Receptor binding

11.1.30 Receptor signaling complex scaffold activity

11.1.31 Receptor signaling protein serine/threonine kinase activity

11.1.32 RNA binding

11.1.33 Structural constituent of cytoskeleton

11.1.34 Superoxide dismutase activity

11.1.35 T cell receptor activity

11.1.36 Transcription factor activity

11.1.37 Transcription regulator activity

11.1.38 Transferase activity

11.1.39 Translation regulator activity

11.1.40 Transmembrane receptor activity

11.1.41 Transmembrane receptor protein tyrosine kinase activity

11.1.42 Transporter activity

12 Apoptopic Drug Target Mix by Development Stage

13 Apoptopic Drug Target Mix by Cancer Indication

13.1 Basal Cell Cancer

13.2 Biliary Cancer

13.3 Bladder Cancer

13.4 Bone Cancer

13.5 Brain Cancer

13.6 Breast Cancer

13.7 Carcinoid Tumor

13.8 Cervical Cancer

13.9 Chemotherapy-induced Neutropenia

13.10 Colorectal Cancer

13.11 Endometrial Cancer

13.12 Fallopian Tube Cancer

13.13 Gastrointestinal Cancer

13.13.1 Gastrointestinal Stomach Cancer

13.13.2 Gastrointestinal Stromal Cancer

13.14 Head and Neck Cancer

13.15 Leukemia

13.15.1 Acute Lymphocytic Leukemia

13.15.2 Acute Myelogenous Leukemia

13.15.3 Chronic Lymphocytic Leukemia

13.15.4 Chronic Myelogenous Leukemia

13.16 Liver Cancer

13.17 Lung Cancer

13.17.1 Non-Small Cell Lung Cancer

13.17.2 Small Cell Lung Cancer

13.18 Lymphoma

13.18.1 B-cell Lymphoma

13.18.2 Hodgkin's Lymphoma

13.18.3 non-Hodgkin's Lymphoma

13.18.4 T-cell Lymphoma

13.19 Melanoma

13.20 Mesothelioma

13.21 Myelodysplastic Syndrome

13.22 Myeloma

13.23 Nasopharyngeal Cancer

13.24 Oesophageal Cancer

13.25 Oral Cancer

13.26 Ovarian Cancer

13.27 Pancreatic Cancer

13.28 Peritoneal Cancer

13.29 Prostate Cancer

13.30 Renal Cancer

13.31 Sarcoma

13.31.1 Leiomyo Sarcoma

13.32 Squamous Cell Cancer

13.33 Testicular Cancer

13.34 Thymoma Cancer

13.35 Thyroid Cancer

14 Apoptopic Drugs and their Targets by Companies

14.1 Australia

14.2 Canada

14.3 China

14.4 Denmark

14.5 Germany

14.6 Israel

14.7 Japan

14.8 South Korea

14.9 Spain

14.10 Switzerland

14.11 Taiwan

14.12 United Kingdom

14.13 USA

15 Breast Cancer: An Introduction

15.1 Disease Definitions

15.2 Etiology

15.3 Epidemiology

15.4 Prognosis

16 Current Treatment Strategies of Breast cancer

16.1 Localized Disease

16.2 Advanced Disease

17 Progress in Current Breast Cancer Treatment Strategies

17.1 Hormone Based Therapies

17.2 Antibodies

17.3 Chemotherapy

17.4 Chemotherapy

18 Key Therapeutic Strategies for Future Breast Cancer Therapies

18.1 Therapeutic Type, Targets & Mechanisms

19 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline

19.1 The Epothilones

19.2 Cell Cycle & Apoptosis

19.3 Protein Kinase Inhibitors

19.4 Immunotherapy

20 Current Drug Development for Breast Cancer: The Early Stage Pipeline

20.1 DNA Targeting

20.2 FTIs

20.3 Antisense

20.4 New Hormone Modulators

20.5 Other

21 Prostate Cancer: An Introduction

21.1 Disease Definitions

21.2 Etiology & Pathophysiology

21.3 Epidemiology

21.4 Prognosis

22 Current Prostate Cancer Treatment Strategies

22.1 Localized Disease

22.1.1 Locally Advanced Prostate Cancer

22.2 Metastatic Prostate Cancer

22.2.1 Hormone-Sensitive Metastatic Prostate Cancer

22.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

23 Progress in Current Prostate Cancer Treatment Strategies

23.1 Long-Term Follow-up Data not yet Been Published

23.2 Significant Reduced Risk of Distant Metastases

23.3 Adverse Events

23.4 No Difference in Overall Survival

23.5 Cross-over Design an Optimal Option?

23.6 Death due to Liver Failure

23.7 Survival Benefit

23.8 Subdermal Implant

23.9 No FDA Approval

23.10 No Improvement in 5-year Disease-Free Survival

23.11 Effective Secondary Hormonal Therapy?

23.12 Synery in Combination

24 Key Therapeutic Strategies for Future Prostate Cancer Therapies

24.1 Therapeutic Type, Targets & Mechanisms

25 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline

25.1 Reduced Prostate Cancer Risk

25.2 High Activity in Metastatic AIPC Patients

25.3 Absence of Severe Toxicities

25.4 Waiting for Data

25.5 Probability of Regulatory Approval?

25.6 Co-development and License Agreement

25.7 Improves Predicted Survival?

25.8 Slow Progress & Development Partners

25.9 Exclusive License Agreement

26 Current Prostate Cancer Drug Development: The Early Stage Pipeline

26.1 New Data?

26.2 Terminated Study

26.3 More Than 50% PSA decline

26.4 Safety and Tolerability

26.5 Terminated?

26.6 Marker of Drug Effect

26.7 Preliminary Results for a Tyrosine Kinase Inhibitor

26.8 No Activity in Monotherapy

26.9 Dramatic Disappearance of Bone Metastatic Lesions

26.10 PSA Response - Anthracycline

27 Disclaimer

28 Drug Index

29 Company Index




List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target

Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census

Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets

Table 4: Pathway Summary

Table 5: Drug Targets Without any Identified Assigned Pathways

Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs

Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta

Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs

Table 9: Drug Targets within the Apoptosis Pathway According to KEGG

Table 10: Apoptopic Drugs Targeting Major Singaling Pathways

Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets

Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets

Table 13: Number of Available Biological Structures on Apoptopic Drug Targets

Table 14: Overview of Drug Target Profile Themes

Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage

Table 16: Apoptopic Drug Target Mixes by Development

Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication

Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug

Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug

Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug

Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug

Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug

Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug

Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug

Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug

Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to the Compound Type and Developmental Stage of Drug

Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug

Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug

Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug

Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug

Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug

Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug

Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug

Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug

Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug

Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug

Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug

Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug

Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug

Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug

Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug

Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug

Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin’s Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug

Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug

Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug

Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug

Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug

Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug

Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug

Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug

Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug

Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug

Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug

Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug

Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug

Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug

Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug

Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug

Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug

Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug

Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug

Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia

Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada

Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China

Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark

Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany

Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel

Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan

Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea

Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain

Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland

Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan

Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom

Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA

Table 64: The Stage System

Table 65: Risk Factors

Table 66: List of Approved Drugs and Their Mechanisms of Action.

Table 67: Hormonal Treatment Strategies

Table 68: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer

Table 69: Treatment Options for Women With Axillary Node-Positive Breast Cancer

Table 70: Chemotherapy Drugs and Regimen

Table 71: Summay of Drugs Involved in Breast Cancer Therapy

Table 72: Short Facts Tamoxifen

Table 73: Short Facts Anastrozole

Table 74: Short Facts Letrozole

Table 75: Short Facts Exemestane

Table 76: Short Facts Goserelin

Table 77: Short Facts Fulvestrant

Table 78: Short Facts Trastuzumab

Table 79 Cancer Immunotherapy Strategies

Table 80: Progress on Ixabepilone

Table 81: Progress on CCI-779

Table 82: Progress on Fenretinide

Table 83: Progress on Lapatinib

Table 84: Progress on Bevacizumab

Table 85: Progress on Theratope

Table 86: Summary of Mid-Stage to Late stage Investigational Agents Under Development

Table 87: Summary of Breast Cancer Early Stage Pipeline

Table 88: The TNM System

Table 89: Lifestyle factors

Table 90: Historical Summary of Clinical Studies on Patients with Late Stage Disease

Table 91: Short Facts Abarelix

Table 92: Short Facts Bicalutamide

Table 93: Short Facts Carboplatin

Table 94: Short Facts Docetaxel

Table 95: Short Facts Mitoxantrone

Table 96: Short Facts Flutamide

Table 97: Short Facts Goserelin

Table 98: Short Facts Histrelin

Table 99: Short Facts Lanreotide

Table 100: Short Facts Leuprolide

Table 101: Short Facts Nilutamide

Table 102: Short Facts Estramustine

Table 103: Summary of Recent Clinical Studies on Patients with Late Stage Disease

Table 104: Ongoing Late Stage Clinical Studies

Table 105: Cancer Immunotherapy Strategies

Table 106: Near Term Progress Toremifene

Table 107: Near Term Progress Bevacizumab

Table 108: Near Term Progress Oblimersen

Table 109: Near Term Progress R-flurbiprofen

Table 110: Near Term Progress APC8015

Table 111: Near Term Progress Satraplatin

Table 112: Near Term Progress GVAX

Table 113: Near Term Progress Exisulind

Table 114: Summary of Prostate Cancer Late Stage Pipeline

Table 115: Paclitaxel

Table 116: Epothilone

Table 117: Ixabepilone

Table 118: PTK/ZK

Table 119: Arsenic trioxide

Table 120: Retinoic Acid

Table 121: Imatinib

Table 122: Bortezomib

Table 123: Sorafenib

Table 124: Doxorubicin

Table 125: Summary of Prostate Cancer Early Stage Pipeline




3.1 List of Boxes

Box 1: Ongoing Phase III Studies Anastrozole

Box 2: Ongoing Phase III Studies Letrozole

Box 3: Ongoing Phase III Studies Exemestane

Box 4: Ongoing Phase III Studies Goserelin

Box 5: Ongoing Phase III Studies Fulvestrant

Box 6: Ongoing Phase III Studies Trastuzumab

Box 7: The TRAIL Receptor family

Box 8: The Bcl-2 family of proteins

Box 9: Quick Facts - BMS-247550

Box 10: Quick Facts - Temsirolimus

Box 11: Quick Facts - SDX-105

Box 12: Quick Facts - 4HPR

Box 13: Quick Facts - Lapatinib

Box 14: Quick Facts - Bevacizumab

Box 15: Quick Facts - Theratope

Box 16: Erlotinib

Box 17: Gefitinib

Box 18: Imatinib

Box 19: Pemetrexed

Box 20: NX473

Box 21: Lonafarnib

Box 22: Tipifarnib

Box 23: Bortezomib

Box 24: Arzoxifene

Box 25: Patupilone

Box 26: KOS-862

Box 27: Southwest Oncology Group Study 99-16 Design

Box 28: TAX 327 Study Design

Box 29: The TRAIL Receptor family

Box 30: The Bcl-2 family of proteins

Box 31: Quick Facts - Toremifene

Box 32: Quick Facts - Bevacizumab

Box 33: Quick Facts - Genasense

Box 34: Quick Facts - R-flurbiprofen

Box 35: Quick Facts - Provenge

Box 36: Quick Facts - Satraplatin

Box 37: Quick Facts - GVAX

Box 38: Quick Facts - Exisulind

Box 39: Quick Facts - Vapreotide

Box 40: Quick Facts - DCVax




3.2 List of Figures

Figure 1: Distribution of Compound Types Among Apoptopic Drugs

Figure 2: Primary Sub-cellular Localization of Drug Targets

Abstract

This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of breast- and prostate cancer. This extensive 450+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further gives an in depth analysis in two key oncology areas; Breast- and Prostate cancer

In the report, BioSeeker reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications. To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.

This report section by the numbers
  • A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
  • 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
  • 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
  • 90 Unique drug target combinations of apoptopic drugs
  • 452 protein-protein interactions among apoptopic drug targets
  • Extensive pathway analysis of drug targets
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been initiated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.

In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.

The Breast and Prostate Cancer section highlights
  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field
  • Key reasons to read this report
This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.

Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008